Vietnam Liquid Embolic Agent Market Report: Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025-2030

Vietnam liquid embolic agent market is valued at USD 12 million, driven by vascular diseases, tech advancements, and minimally invasive procedures in key cities like Hanoi and Ho Chi Minh.

The Vietnam Liquid Embolic Agent Market is valued at approximately USD 12 million, based on a five-year historical analysis. This growth is primarily driven by the increasing prevalence of vascular diseases, advancements in medical technology, and a growing number of interventional procedures. The rising awareness of minimally invasive treatment options among healthcare professionals and patients has further fueled the demand for liquid embolic agents in the country. The global market context shows strong growth in minimally invasive therapies, with Asia Pacific as the fastest-growing region, which likely influences Vietnam’s adoption trends.

Key cities such as Ho Chi Minh City and Hanoi dominate the market due to their advanced healthcare infrastructure and concentration of specialized medical facilities. These urban centers are home to numerous hospitals and clinics that offer interventional radiology services, making them critical hubs for the distribution and utilization of liquid embolic agents.

In 2023, the Vietnamese government implemented the Law on Medical Devices (No. 98/2021/QH15), issued by the National Assembly, which mandates that all medical devices, including liquid embolic agents, must undergo registration, quality testing, and approval by the Ministry of Health before market entry. Compliance requires manufacturers and importers to submit technical dossiers, clinical evaluation data, and post-market surveillance plans. The law also establishes licensing requirements for distributors and enforces Good Distribution Practices (GDP) to ensure product traceability and patient safety throughout the supply chain.

Vietnam Liquid Embolic Agent Market Segmentation

By Type:

The market is segmented into various types of liquid embolic agents, including N-butyl cyanoacrylate (NBCA), ethylene vinyl alcohol copolymer (EVOH), polyvinyl alcohol (PVA) particles, non-adhesive liquid embolics, and others. Among these, N-butyl cyanoacrylate (NBCA) and ethylene vinyl alcohol copolymer (EVOH) are the most widely used due to their effectiveness in various embolization procedures and established safety profiles. The increasing adoption of these agents in clinical settings is driven by their versatility and the growing number of interventional radiology procedures. Cyanoacrylates, including NBCA, are experiencing the fastest growth globally, which may reflect similar trends in Vietnam as advanced products become more accessible.

By Application:

The applications of liquid embolic agents include arteriovenous malformations (AVMs), tumor embolization, aneurysm treatment, gastrointestinal bleeding, uterine fibroid embolization, and others. Tumor embolization is the leading application segment, driven by the rising incidence of various cancers and the increasing preference for minimally invasive treatment options. The effectiveness of liquid embolic agents in targeting tumors has made them a preferred choice among healthcare providers. Globally, AVMs represent a significant application segment, but in Vietnam, tumor embolization may lead due to the high burden of liver and other cancers requiring interventional therapy.

Vietnam Liquid Embolic Agent Market Competitive Landscape

The Vietnam Liquid Embolic Agent Market is characterized by a dynamic mix of regional and international players. Leading participants such as Medtronic, Boston Scientific Corporation, Johnson & Johnson (DePuy Synthes/Codman Neuro), Terumo Corporation, Cook Medical, Merit Medical Systems, Stryker Corporation, AngioDynamics, Penumbra, Inc., Asahi Intecc Co., Ltd., B. Braun Melsungen AG, Abbott Laboratories, Hologic, Inc., GE HealthCare, Siemens Healthineers, Balt Group, MicroVention, Inc. (Terumo Group), GEM Srl, BlackSwan Vascular, Inc., INVAMED contribute to innovation, geographic expansion, and service delivery in this space.

Vietnam Liquid Embolic Agent Market Industry Analysis

Growth Drivers

Increasing Prevalence of Vascular Diseases:

The rise in vascular diseases in Vietnam is significant, with over 1.5 million cases reported annually. According to the World Health Organization, cardiovascular diseases account for approximately 33% of total deaths in the country. This alarming statistic drives the demand for effective treatment options, including liquid embolic agents, as healthcare providers seek innovative solutions to manage these conditions effectively and improve patient outcomes.

Advancements in Medical Technology:

Vietnam's healthcare sector is experiencing rapid technological advancements, with investments reaching $1.5 billion in future. Innovations in liquid embolic agents, such as improved formulations and delivery systems, enhance treatment efficacy and safety. The integration of cutting-edge technologies, including imaging and minimally invasive techniques, is expected to further boost the adoption of these agents, making them a preferred choice for healthcare professionals in the region.

Rising Healthcare Expenditure:

Vietnam's healthcare expenditure is projected to reach $20 billion in future, reflecting a growing commitment to improving health services. This increase in funding allows for better access to advanced medical treatments, including liquid embolic agents. As the government prioritizes healthcare improvements, hospitals and clinics are more likely to invest in innovative solutions, driving the market for liquid embolic agents forward in the coming years.

Market Challenges

High Cost of Liquid Embolic Agents:

The high cost of liquid embolic agents poses a significant barrier to widespread adoption in Vietnam. Prices can range from $1,000 to $3,000 per treatment, making them less accessible for many patients. This financial burden can deter healthcare providers from recommending these treatments, especially in a market where cost-effectiveness is a critical consideration for both patients and healthcare systems.

Regulatory Hurdles:

The regulatory landscape for medical devices in Vietnam is complex, with stringent approval processes that can delay the introduction of new liquid embolic agents. The Ministry of Health requires extensive clinical data and compliance with international standards, which can take years to fulfill. These regulatory challenges can hinder innovation and slow market growth, as companies may be reluctant to invest in new product development under such conditions.

Vietnam Liquid Embolic Agent Market Future Outlook

The future of the Vietnam liquid embolic agent market appears promising, driven by increasing healthcare investments and a growing focus on advanced medical technologies. As the government continues to enhance healthcare infrastructure, the accessibility of liquid embolic agents is expected to improve. Additionally, the rising demand for personalized medicine and targeted therapies will likely create new avenues for growth, encouraging innovation and collaboration among industry stakeholders to meet evolving patient needs.

Market Opportunities

Expansion of Healthcare Infrastructure:

The Vietnamese government plans to invest $5 billion in healthcare infrastructure by future. This investment will enhance access to advanced medical treatments, including liquid embolic agents, particularly in rural areas. Improved facilities and resources will facilitate the adoption of these technologies, ultimately benefiting patient care and driving market growth.

Collaborations with Research Institutions:

Collaborations between pharmaceutical companies and research institutions are on the rise, with over 30 partnerships established in future. These collaborations aim to develop innovative liquid embolic agents and improve treatment protocols. By leveraging academic expertise and resources, companies can accelerate product development and enhance their competitive edge in the market.